US FDA declines to approve Aldeyra's eye disease drug
03/04/2025 13:05
April 3 (Reuters) - The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' ALDX.O treatment for dry eye disease, the company said on Thursday. (Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser